// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Short and long-term surgical outcomes and pouch function following proctocolectomy and pouch formation in paediatric ulcerative colitis: a multicentre-retrospective cohort study from the Porto IBD working group of ESPGHAN

E. Orlanski Meyer - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Treating beyond symptoms in inflammatory bowel disease (IBD): the Kent IBD Nurse Experience with the Steroid assessment tool

G. Scott - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Indirect comparison of two novel biologics for the treatment of Crohn's disease : network-meta analysis of ustekinumab vs vedolizumab

G. Hather - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey

S. Danese - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

S. Travis - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adalimumab

Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States

H. Patel - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease

K. Mortier - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice

S. Ben-Horin - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Female gender, somatization and presence of IBS-type symptoms predicts Dyspareunia in patients with IBD

A. O'Connor - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Do self-selected “Non-Transitioned” referrals from peadiatric services have lower treatment requirements?

O. Shaikh - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry

G. D'Haens - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Adalimumab

Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries

S. Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study

S. McCartney - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience

U. Kopylov - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients

K. Keetarut - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?

H. Johnson - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Oraprine

Open-label study to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients with Clostridium difficile infection (the PROFILE study): pharmacokinetics analysis

C. Hgenauer - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Fidaxomicin

Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom

N. Kamperidis - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatment

K. Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's disease

N. Heerasing - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved